Literature DB >> 12939642

Biased epitope selection by recombinant vaccinia-virus (rVV)-infected mature or immature dendritic cells.

D Nagorsen1, M Panelli, M E Dudley, S E Finkelstein, S A Rosenberg, F M Marincola.   

Abstract

Recombinant expression vectors represent a powerful way to deliver whole antigens (Ags) for immunization. Sustained Ag expression in vector-infected dendritic cells (DC) combines Ag-specific stimulation with powerful costimulation and, simultaneously, through 'self-selection' of ad hoc epitopes broadens the scope of immunization beyond restrictions posed by individual patients' human leukocyte antigen (HLA) phenotype. In this study, therefore, we evaluated the efficiency of a recombinant vaccinia virus encoding the gp100/PMel17 melanoma Ag (rVV-gp100) to infect immature (iDC) or mature dendritic cells (mDC) derived from circulating mononuclear cells and the effect of infection on their status of maturation. In addition, we tested the ability of rVV-gp100-infected iDC and mDC to present the HLA-A*0201-associated gp100:209-217 epitope (g209). Irrespective of status of maturation, rVV-gp100 infection induced gp100 expression while only partially reversing the expression of some maturation markers. However, endogenous presentation of the wild-type g209 epitope was inefficient. The low efficiency was epitope-specific since infection of DC with rVV encoding a gp100 construct containing the modified gp100:209-217 (210M) (g209-2M) epitope characterized by high binding affinity for HLA-A*0201 restored efficient Ag presentation. Presentation of an HLA-class II-associated epitope and cytokine release by DC was not altered by rVV infection. Thus, Ag expression driven by rVV may be an efficient strategy for whole Ag delivery. However, since the effectiveness of Ag processing and presentation is subject to stringent HLA/epitope pairing, and for other yet undefined rules, the assumption that whole Ag delivery may circumvent HLA restriction is incorrect and recombinant expression vectors encoding well-characterized polyepitopic constructs may prove more effective.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12939642      PMCID: PMC2275329          DOI: 10.1038/sj.gt.3302066

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  63 in total

Review 1.  Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance.

Authors:  F M Marincola; E M Jaffee; D J Hicklin; S Ferrone
Journal:  Adv Immunol       Date:  2000       Impact factor: 3.543

2.  Natural adjuvants: endogenous activators of dendritic cells.

Authors:  S Gallucci; M Lolkema; P Matzinger
Journal:  Nat Med       Date:  1999-11       Impact factor: 53.440

3.  Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues.

Authors:  D Valmori; J F Fonteneau; S Valitutti; N Gervois; R Dunbar; D Liénard; D Rimoldi; V Cerundolo; F Jotereau; J C Cerottini; D E Speiser; P Romero
Journal:  Int Immunol       Date:  1999-12       Impact factor: 4.823

Review 4.  From TCR engagement to T cell activation: a kinetic view of T cell behavior.

Authors:  A Lanzavecchia; G Iezzi; A Viola
Journal:  Cell       Date:  1999-01-08       Impact factor: 41.582

5.  Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue.

Authors:  D Valmori; F Lévy; I Miconnet; P Zajac; G C Spagnoli; D Rimoldi; D Liénard; V Cerundolo; J C Cerottini; P Romero
Journal:  J Immunol       Date:  2000-01-15       Impact factor: 5.422

6.  Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion.

Authors:  H A Coller; C Grandori; P Tamayo; T Colbert; E S Lander; R N Eisenman; T R Golub
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

7.  Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression.

Authors:  K H Lee; E Wang; M B Nielsen; J Wunderlich; S Migueles; M Connors; S M Steinberg; S A Rosenberg; F M Marincola
Journal:  J Immunol       Date:  1999-12-01       Impact factor: 5.422

8.  Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion.

Authors:  J Engelmayer; M Larsson; M Subklewe; A Chahroudi; W I Cox; R M Steinman; N Bhardwaj
Journal:  J Immunol       Date:  1999-12-15       Impact factor: 5.422

9.  Antitumor immunization with a minimal peptide epitope (G9-209-2M) leads to a functionally heterogeneous CTL response.

Authors:  M E Dudley; M I Nishimura; A K Holt; S A Rosenberg
Journal:  J Immunother       Date:  1999-07       Impact factor: 4.456

10.  Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells.

Authors:  B Sauter; M L Albert; L Francisco; M Larsson; S Somersan; N Bhardwaj
Journal:  J Exp Med       Date:  2000-02-07       Impact factor: 14.307

View more
  7 in total

Review 1.  Understanding the response to immunotherapy in humans.

Authors:  Ena Wang; Monica C Panelli; Francesco M Marincola
Journal:  Springer Semin Immunopathol       Date:  2005-01-22

2.  Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma.

Authors:  Jianda Yuan; Geoffrey Y Ku; Humilidad F Gallardo; Francesca Orlandi; Gregor Manukian; Teresa S Rasalan; Yinyan Xu; Hao Li; Shachi Vyas; Zhenyu Mu; Paul B Chapman; Susan E Krown; Katherine Panageas; Stephanie L Terzulli; Lloyd J Old; Alan N Houghton; Jedd D Wolchok
Journal:  Cancer Immun       Date:  2009-06-05

3.  Clinical opportunities in combining immunotherapy with radiation therapy.

Authors:  Steven E Finkelstein; Mayer Fishman
Journal:  Front Oncol       Date:  2012-11-26       Impact factor: 6.244

Review 4.  Long-term gene expression in dividing and nondividing cells using SV40-derived vectors.

Authors:  David S Strayer; Lokesh Agrawal; Pierre Cordelier; Bianling Liu; Jean-Pierre Louboutin; Elena Marusich; Hayley J McKee; Carmen N NiGongyi Ren; Marlene S Strayer
Journal:  Mol Biotechnol       Date:  2006-10       Impact factor: 2.860

5.  Identification and characterization of a novel nasopharyngeal carcinoma-associated peptide: NAP-1.

Authors:  Feng Li; Xu Y Yang; Wei H Jiang; Zhi H Yin; Xiang L Feng; Wei D Liu; Lei Wang; Wen Zhou; Cai P Ren; Kai T Yao
Journal:  J Transl Med       Date:  2004-04-07       Impact factor: 5.531

Review 6.  Progresses towards safe and efficient gene therapy vectors.

Authors:  Sergiu Chira; Carlo S Jackson; Iulian Oprea; Ferhat Ozturk; Michael S Pepper; Iulia Diaconu; Cornelia Braicu; Lajos-Zsolt Raduly; George A Calin; Ioana Berindan-Neagoe
Journal:  Oncotarget       Date:  2015-10-13

Review 7.  Targeting the porcine immune system--particulate vaccines in the 21st century.

Authors:  Kenneth C McCullough; Artur Summerfield
Journal:  Dev Comp Immunol       Date:  2008-09-02       Impact factor: 3.636

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.